Targeted Therapy for Blood Cancer Patients
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Progress Against Cancer
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) recently approved the molecularly targeted therapeutic zanubrutinib (Brukinsa) for the...
The FDA approved the immune checkpoint inhibitor pembrolizumab in combination with the molecularly targeted therapeutic lenvatinib for women with advanced endometrial cancer.
The most impactful and informative cancer reporting and essays of 2019 selected by the editors of Cancer Today magazine.
In 2019, research continued to drive progress across the spectrum of cancer care in the form of new and better ways to prevent, detect, diagnose, and treat some of the many diseases we call cancer. Here’s a look at some key developments in drug approvals, precision medicine, disparities research, and immunotherapy.
Urologist Ardeshir Rastinehad, DO, is developing an alternative to standard laser therapy to help prostate cancer patients avoid side effects like urinary incontinence and erectile dysfunction.
New law mandates that cancer drugs get tested in kids in clinical trials.
Researchers are studying how best to support cancer caregivers.
Research indicates that only a small percentage of high-risk individuals eligible for lung cancer screening actually undergo a scan.
A new study explores the impact of lowering a patient's dose due to side effects.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More